Common mutations in BRCAI and BRCA2 do not contribute to early prostate cancer in Jewish men

Prostate

Volumn 40, Issue 3, 1999, Pages 172-177

  Nastiuk, Kent L ^a,e   Mansukhani, Mahesh ^a   Terry, Mary Beth ^b   Kularatne, Piyumika ^a   Rubin, Mark A ^a   Melamed, Jonathan ^c   Gammon, Marilie D ^b   Ittmann, Michael ^c,d,f   Krolewski, John J ^a,e  

^a Columbia University ^*  (United States)

^b New York State Psychiatric Institute   (United States)

^c NEW YORK UNIVERSITY   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Breast; Gene; Heterozygote; Neoplastic; Risk

Indexed keywords

ADULT; ARTICLE; CANCER RISK; CONTROLLED STUDY; GENE MUTATION; GENETIC RISK; HETEROZYGOSITY; HUMAN; HUMAN TISSUE; JEW; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTO ONCOGENE;

ADULT; BRCA2 PROTEIN; EUROPE; EXONS; GENES, BRCA1; GENETIC MARKERS; GENOTYPE; GERM-LINE MUTATION; HUMANS; INCIDENCE; INTRONS; JEWS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; NEW YORK CITY; PROSTATIC NEOPLASMS; SEQUENCE DELETION; TRANSCRIPTION FACTORS;

EID: 0032764893     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/(sici)1097-0045(19990801)40:3<172::aid-pros5>3.0.co;2-r     Document Type: Article

References (31)

1. Struewing JP, Hartge P, Wacholder S, Baker SIM, Berlin M, McAdams M, Timmerman MM, Brody LC, Tucker MA. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 1997;336:1401-1408.
2. Ford D, Easton DF, Bishop DT, Narod SA, Goldgar DE, Breast Cancer Linkage Consortium. Risks of cancer in BRCA1-mutation carriers. Lancet 1994;343:692-695.
3. Arason A, Barkardottir RB, Egilsson V. Linkage analysis of chromosome 17q markers and breast-ovarian cancer in Icelandic families, and possible relationship to prostatic cancer. Am J Hum Genet 1993;52:711-717.
4. Friedman LS, Szabo CI, Ostermeyer EA, Dowd P, Butler L, Park T, Lee MK, Goode EL, Rowell SE, King M-C. Novel inherited mutations and variable expressivity of BRCA1 alleles, including the founder mutation 185delAG in Ashkenazi Jews. Am J Hum Genet 1995;57:1284-1297.
5. Brothman AR, Steele MR, Williams BJ, Jones E, Odelberg S, Albertsen HM, Jorde LB, Rohr LR, Stephenson RA. Loss of chromosome 17 loci in prostate cancer detected by polymerase chain reaction quantitation of allelic markers. Genes Chromosom Cancer 1995;13:278-284.
6. Gao X, Zacharek A, Salkowski A, Grignon DJ, Sakr W, Porter AT, Honn KV. Loss of heterozygosity of the BRCA1 and other loci on chromosome 17q in human prostate cancer. Cancer Res 1995;55:1002-1005.
7. Ittmann MM. Loss of heterozygosity on chromosomes 10 and 17 in clinically localized prostate carcinoma. Prostate 1996;28:275-281.
8. Gudmundsson J, Johannesdottir G, Bergthorsson JT, Arason A, Ingvarsson S, Egilsson V, Barkardottir RB. Different tumor types from BRCA2 carriers show wild-type chromosome deletions on 13q12-q13. Cancer Res 1995;55:4830-4832.
9. Cooney KA, Wetzel JC, Merajver SD, Macoska JA, Singelton TP, Wojno KJ. Distinct regions of allelic loss on 13q in prostate cancer. Cancer Res 1996;56:1142-1145.
10. Ittmann MM, Wieczorek R. Alterations of the retinoblastoma gene in clinically localized, stage B prostate adenocarcinomas. Hum Pathol 1996;27:28-34.
11. Williams BJ, Jones E, Zhu XL, Steele MR, Stephenson RA, Rohr LR, Brothman AR. Evidence for a tumor suppressor gene distal to BRCA1 in prostate cancer. J Urol 1996;155:720-725.
12. Gao X, Zacharek A, Grignon DJ, Sakr W, Powell IJ, Porter AT, Honn KV. Localisation of potential tumor suppressor loci to a <2 Mb region on chromosome 17q in human prostate cancer. Oncogene 1995;11:1241-1247.
13. Murakami YS, Brothman AR, Leach RJ, White RL. Suppression of malignant phenotype in a human prostate cancer cell line by fragments of normal chromosome region 17q. Cancer Res 1995; 55:3389-3394.
14. Struewing JP, Abeliovich D, Peretz T, Avishai N, Kaback MM, Collins FS, Brody LC. The carrier frequency of the BRCA1 185delAG mutation is approximately 1 percent in Ashkenazi Jewish individuals. Nat Genet 1995;11:198-200.
15. Roa BB, Boyd AA, Volcik K, Richards CS. Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2. Nat Genet 1996;14:185-187.
16. Wooster R, Bignell G, Lancaster J, Swift S, Seal S, Mangion J, Collins N, Gergory S, Gumbs C, Micklem G, Barfoot R, Hamoudi R, Patel S, Rice C, Biggs P, Hashim Y, Smith A, Connor F, Arason A, Gudmundsson J, Ficenec D, Kelsell D, Ford D, Tonin P, Bishop DT, Spurr N, Ponder BAJ, Eeles R, Peto J, Devilee P, Cees C, Lynch F, Narod S, Lenoir G, Egilsson V, Barkadottir RB, Easton DF, Bentley DR, Futreal PA, Ashworth A, Stratton MR. Identification of the cancer susceptibility gene BRCA2. Nature 1995;378:789-791.
17. Oddoux C, Struewing JP, Clayton CM, Neuhausen S, Brodyu L, Kaback M, Haas B, Norton L, Borgen P, Jhanwar S, Goldgar D, Ostrer H, Offit K. The carrier frequency of the BRCA2 6174delT mutation among Ashkenazi Jewish individuals is approximately 1%. Nat Genet 1996;14:188-190.
18. Johannesdottir G, Gudmundsson J, Bergthorsson JT, Arason A, Agnarsson BA, Eiriksdottir G, Johansson OT, Borg A, Ingvarsson S, Easton DF, Egilsson V, Barkardottir RB. High prevalence of the 999del5 mutation in Icelandic breast and ovarian cancer patients. Cancer Res 1996;56:3663-3665.
19. Easton DF, Ford D, Bishop TD, Breast Cancer Linkage Consortium. Breast land ovarian cancer incidence in BRCA1-mutation carriers. Am J Hum Genet 1995;56:265-271.
20. Mansukhani M, Nastiuk KL, Hibshoosh H, Kularatne P, Russo D, Krolewski JJ. Convenient, non-radioactive, heteroduplex-based methods for identifying recurrent mutations in the BRCA1 and BRCA2 genes. Diagn Mol Pathol 1997;6:229-237.
21. Phelan CM, Lancaster JA, Tonin P, Gumbs C, Cochran C, Carter R, Ghadirian P, Perret C, Moslehi R, Dion F, Faucher M-C, Dole K, Karimi S, Foulkes W, Lounis H, Warner E, Goss P, Anderson D, Larsson C, Narod SA, Futreal PA. Mutation analysis of the BRCA2 genelin 49 site-specific breast cancer families. Nat Genet 1996;13:120-122.
22. Easton DF, Steele L, Fields P, Ormiston W, Averill D, Daly PA, McManus R, Neuhausen SL, Ford D, Wooster R, Cannon-Albright LA, Stratton MR, Goldgar DE. Cancer risks in two large breast cancer families linked to BRCA2 on chromosome 13q12-13. Am J Hum Genet 1997;61:120-128.
23. Sigurdsson S, Thorlacius S, Tomasson J, Tryggvadottir L, Benedictsdottir K, Eyfjord JE, Johsson E. BRCA2 mutation in Icelandic protate cancer patients. J Mol Med 1997;75:758-761.
24. FitzGerald MG, MacDonald DJ, Krainer M, Hoover I, O'Neil E, Unsal H, Sila-Arrieto S, Finkelstein DM, Beer-Romero P, Englert C, Scroi DC, Smith BL, Younger JW, Garber JE, Duda RB, Mayzel KA, Isselbacher KJ, Friend SH, Haber DA. Germ-line BRCA1 mutations in Jewish and non-Jewish women with early-onset breast cancer. N Engl J Med 1996;334:143-149.
25. Langston AA, Stanford JL, Wicklund KG, Thompson JD, Blazej RG, Ostrander EA. Germ-line BRCA1 mutations in selected men with prostate cancer. Am J Hum Genet 1996;58:881-885.
26. Neuhausen S, Gilewski T, Norton L, Tran T, McGuire P, Swensen L, Hampel H, Borgen P, Brown K, Skolnick M, Shattuck-Eidens D, Jhanwar S, Goldgar D, Offit K. Recurrent BRCA2 6174delT mutations in Ashkenazi Jewish women affected by breast cancer. Nat Genet 1996;13:126-128.
27. Gittes RF. Carcinoma of the prostate. N Engl J Med 1991;324: 1892-1893.
28. FitzGerald MG, Bean JM, Hegde SR, Unsal H, MacDonald DJ, Harkin DP, Finkelstein DM, Isselbacher KJ, Haber DA. Heterozygous ATM mutations do not contribute to early onset of breast cancer. Nat Genet 1997;15:307-310.
29. Melamed J, Einhorn JM, Ittmann MM. Allelic loss on chromosome 13q in human prostate cancer. Clin Cancer Res 1997;3: 1867-1872.
30. Li C, Larsson C, Futreal A, Lancaster J, Phelan C, Aspenblad U, Sindelin B, Liu Y, Ekman P, Auer G, Bergerheim USR. Identification of two distinct deleted regions on chromosome 13 in prostate cancer. Oncogene 1998;16:481-487.
31. Lehrer S, Fodor F, Stock RG, Stone NN, Eng C, Song HK, McGovern M. Absence of 185delAG mutation of the BRCA1 gene and 6174delT mutation of the BRCA2 gene in Ashkenazi Jewish men with prostate cancer. Br J Cancer 1998;78:771-773.